Who is sponsoring NCT00021021?

NCT00021021 is sponsored by Ribozyome.

What condition does NCT00021021 study?

NCT00021021 studies Kidney Cancer.

What drugs are being tested in NCT00021021?

Interventions: anti-FLT-1 ribozyme.

What is the status of NCT00021021?

NCT00021021 is currently COMPLETED.

Last reviewed 2013-03-25 · How we verify

A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer

NCT00021021 Phase 2 COMPLETED

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

Details

Lead sponsor	Ribozyome
Phase	Phase 2
Status	COMPLETED
Start date	2001-09
Completion	2004-02

Conditions

Kidney Cancer

Interventions

anti-FLT-1 ribozyme

Countries

United States